What is PTC Therapeutics, Inc.'s earnings per share (EPS)?

PTC Therapeutics, Inc. (PTCT) reported diluted earnings per share of $7.78 for fiscal year 2025. This represents a 264.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PTC Therapeutics, Inc. (PTCT) Financials

PTCT

Trailing 12 months to June 30, 2026

Revenue $1.0B -42.8% YoY

Net Income -$38.0M -106.0% YoY

EPS (Diluted) $7.78 FY2025 annual

Free Cash Flow -$39.8M -105.7% YoY

Market Cap $5.4B as of Oct 10, 2026

Price / Sales 5.4x on $1.0B revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PTCT SEC filings page.

PTC Therapeutics, Inc. (PTCT) reported $1.0B in revenue over the twelve months to Jun 30, 2026, down 42.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PTCT FY2025 2026-10-04

PTC shifted from sustained losses to cash-generating profitability in FY2025, but accumulated deficits still leave liabilities above assets.

The FY2025 earnings inflection was unusually cash-backed: net income of $683M was close to operating cash flow of $711M, while free cash flow also stayed near that level. That reverses FY2024’s cash-consuming pattern and indicates the reported profit translated into funds retained by the business rather than existing mainly through accounting entries.

Operating leverage changed sharply: operating margin moved from -37.5% in FY2024 to 50.1% in FY2025 as research and development spending declined, so the inflection reflects both much higher revenue and lower reported development spending—not scale alone.

Liquidity and solvency tell different stories: a current ratio of 2.3x means near-term assets exceeded near-term obligations, yet negative equity of $205M shows total liabilities still exceeded total assets, leaving the balance sheet structurally weaker than its short-term coverage suggests.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of PTC Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

PTC Therapeutics, Inc. has an operating margin of 50.1%, meaning the company retains $50 of operating profit per $100 of revenue. This results in a moderate score of 43/100, indicating healthy but not exceptional operating efficiency. This is up from -37.5% the prior year.

Growth

PTC Therapeutics, Inc.'s revenue surged 114.5% year-over-year to $1.7B, reflecting rapid business expansion. This strong growth earns a score of 92/100.

Leverage

Not available for PTC Therapeutics, Inc., and counted as zero in the overall score.

Liquidity

With a current ratio of 2.35, PTC Therapeutics, Inc. holds $2.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 67/100.

Cash Flow

PTC Therapeutics, Inc. converts 40.6% of revenue into free cash flow ($702.3M). This strong cash generation earns a score of 71/100.

Returns

Altman Z-Score Distress

1.74

PTC Therapeutics, Inc. scores 1.74, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.4B) relative to total liabilities ($3.1B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/7

PTC Therapeutics, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.04x

For every $1 of reported earnings, PTC Therapeutics, Inc. generates $1.04 in operating cash flow ($711.2M OCF vs $683.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.69x

PTC Therapeutics, Inc. earns $5.69 in operating income for every $1 of interest expense ($866.9M vs $152.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$360.5M

YoY+101.5%

QoQ+32.3%

5Y CAGR+25.3%

10Y CAGR+36.9%

PTC Therapeutics, Inc. generated $360.5M in revenue in Q2 2026. This represents an increase of 101.5% from the same quarter a year earlier. Against the prior quarter it is up 32.3%.

EBITDA

$164.9M

YoY+702.2%

QoQ+173.1%

PTC Therapeutics, Inc.'s EBITDA was $164.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 702.2% from the same quarter a year earlier. Against the prior quarter it is up 173.1%.

Net Income

$83.5M

YoY+228.8%

QoQ+3072.4%

PTC Therapeutics, Inc. reported $83.5M in net income in Q2 2026. This represents an increase of 228.8% from the same quarter a year earlier. Against the prior quarter it is up 3072.4%.

EPS (Diluted)

$0.92

YoY+210.8%

PTC Therapeutics, Inc. earned $0.92 per diluted share (EPS) in Q2 2026. This represents an increase of 210.8% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

$126.9M

YoY+313.0%

QoQ+310.7%

PTC Therapeutics, Inc. generated $126.9M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 313.0% from the same quarter a year earlier. Against the prior quarter it is up 310.7%.

Cash & Debt

$1.0B

YoY+3.2%

QoQ+25.9%

5Y CAGR+42.7%

10Y CAGR+40.2%

PTC Therapeutics, Inc. held $1.0B in cash against $535.5M in long-term debt as of Q2 2026.

Shares Outstanding

83M

YoY+5.1%

5Y CAGR+3.4%

10Y CAGR+9.3%

PTC Therapeutics, Inc. had 83M shares outstanding in Q2 2026. This represents an increase of 5.1% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

41.3%

YoY+60.9pp

QoQ+24.8pp

5Y change+125.7pp

PTC Therapeutics, Inc.'s operating margin was 41.3% in Q2 2026, reflecting core business profitability. This is up 60.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.8 percentage points.

Net Margin

23.2%

YoY+59.4pp

QoQ+24.2pp

PTC Therapeutics, Inc.'s net profit margin was 23.2% in Q2 2026, showing the share of revenue converted to profit. This is up 59.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$99.2M

YoY-12.2%

QoQ-1.7%

5Y CAGR-4.6%

PTC Therapeutics, Inc. invested $99.2M in research and development in Q2 2026. This represents a decrease of 12.2% from the same quarter a year earlier. Against the prior quarter it is down 1.7%.

Capital Expenditures

$2.2M

YoY+75.8%

QoQ+83.1%

5Y CAGR-22.8%

10Y CAGR+71.4%

PTC Therapeutics, Inc. invested $2.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 75.8% from the same quarter a year earlier. Against the prior quarter it is up 83.1%.

Share Buybacks

Not reported for Q2 2026.

PTCT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PTCT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.0B	$1.7B+114.5%	$806.8M-14.0%	$937.8M+34.2%	$698.8M+29.7%	$538.6M+41.4%	$380.8M+24.0%	$307.0M+16.0%	$264.7M+36.2%	$194.4M+135.0%	$82.7M+124.9%	$36.8M+45.6%	$25.2M-27.2%	$34.7M+2.2%	$33.9M-67.8%	$105.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$12.1M-4.2%	$12.7M+176.8%	$4.6M	$0	$0	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$294.8M+17.0%	$252.1M+32.8%	$189.8M+129.5%	$82.7M+124.9%	$36.8M	N/A	N/A	N/A	N/A
R&D Expenses	$433.3M	$455.2M-14.8%	$534.5M-19.8%	$666.6M+2.3%	$651.5M+20.5%	$540.7M+13.2%	$477.6M+85.5%	$257.5M+49.7%	$172.0M+46.4%	$117.5M-0.2%	$117.6M-3.4%	$121.8M+52.6%	$79.8M+45.5%	$54.9M+18.9%	$46.1M-21.4%	$58.7M
SG&A Expenses	$347.7M	$347.1M+15.4%	$300.9M-9.5%	$332.5M+2.0%	$326.0M+14.1%	$285.8M+16.6%	$245.2M+21.0%	$202.5M+31.9%	$153.5M+26.6%	$121.3M+24.9%	$97.1M+18.3%	$82.1M+83.1%	$44.8M+77.7%	$25.2M+72.6%	$14.6M-9.5%	$16.2M
Operating Income	$125.6M	$866.9M+386.5%	-$302.6M+31.2%	-$439.5M+1.8%	-$447.4M-19.5%	-$374.4M+13.3%	-$431.8M-79.0%	-$241.2M-108.5%	-$115.7M-79.9%	-$64.3M+51.3%	-$132.1M+21.0%	-$167.1M-68.1%	-$99.4M-119.0%	-$45.4M-69.3%	-$26.8M-187.7%	$30.6M
EBITDA	N/A	$905.8M+499.2%	-$226.9M-11.8%	-$202.9M+36.3%	-$318.6M-2.7%	-$310.3M+20.1%	-$388.3M-85.8%	-$209.0M-133.2%	-$89.6M-92.2%	-$46.6M+63.8%	-$128.8M+21.6%	-$164.3M-69.0%	-$97.2M-126.0%	-$43.0M-78.4%	-$24.1M-172.1%	$33.5M
Interest Expense	$185.3M	$152.2M-8.8%	$167.0M+29.3%	$129.2M+42.2%	$90.9M+5.6%	$86.0M+52.7%	$56.4M+351.1%	$12.5M-0.5%	$12.6M+3.8%	$12.1M+46.1%	$8.3M+249.6%	$2.4M	N/A	$6.1M+402.8%	$1.2M-50.5%	$2.4M
Income Tax	-$28.7M	$14.0M+7840.3%	$176K+100.3%	-$69.5M-144.1%	-$28.5M-612.0%	$5.6M-84.2%	$35.2M+202.4%	$11.7M+40272.4%	-$29K-102.2%	$1.3M+134.6%	$569K+17.3%	$485K+110.3%	-$4.7M	N/A	N/A	-$2.3M
Net Income	-$38.0M	$683.0M+288.0%	-$363.3M+42.0%	-$626.6M-12.1%	-$559.0M-6.7%	-$523.9M-19.6%	-$438.2M-74.2%	-$251.6M-96.4%	-$128.1M-62.1%	-$79.0M+44.4%	-$142.1M+16.6%	-$170.4M-81.8%	-$93.8M-81.8%	-$51.6M-96.6%	-$26.2M-184.9%	$30.9M
EPS (Basic)	N/A	$8.58+281.4%	-$4.73+43.5%	-$8.37-7.4%	-$7.79-4.8%	-$7.43-11.9%	-$6.64-55.5%	-$4.27-55.3%	-$2.75-36.1%	-$2.02	N/A	N/A	-$2.97+42.7%	-$5.18-102.4%	$219.76+817.6%	$23.95
EPS (Diluted)	—	$7.78+264.5%	-$4.73+43.5%	-$8.37-7.4%	-$7.79-4.8%	-$7.43-11.9%	-$6.64-55.5%	-$4.27	N/A	N/A	N/A	N/A	-$2.97	-$5.18	$42.50+834.1%	$4.55
Diluted Shares (Avg)	N/A	88M+14.9%	77M+2.7%	75M+4.3%	72M+1.8%	70M+6.7%	66M+12.2%	59M	N/A	N/A	N/A	N/A	32M	13M	17,205+200.3%	5,729

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$360.5M+101.5%	$272.6M-76.8%	$164.7M-22.7%	$211.0M+7.2%	$178.9M-4.2%	$1.2B+459.7%	$213.2M-30.6%	$196.8M+0.1%
R&D Expenses	$99.2M-12.2%	$100.9M-7.4%	$133.1M+6.7%	$100.2M-37.9%	$113.0M-14.5%	$109.0M-6.2%	$124.8M+2.8%	$161.4M-1.7%
SG&A Expenses	$80.6M-5.4%	$86.2M+6.5%	$96.9M+14.4%	$84.0M+14.4%	$85.3M+22.7%	$81.0M+10.5%	$84.7M+11.0%	$73.5M-9.2%
Operating Income	$149.0M+526.2%	$45.0M-95.4%	-$71.3M+56.1%	$3.0M+105.5%	-$35.0M+13.1%	$970.2M+2234.6%	-$162.4M-2890.2%	-$54.5M+53.9%
EBITDA	$164.9M+702.2%	$60.4M-93.8%	-$58.4M+62.4%	$14.1M+129.4%	-$27.4M+17.5%	$977.4M+9731.5%	-$155.6M-279.9%	-$48.0M+14.4%
Interest Expense	$48.5M+59.7%	$49.0M+43.8%	$55.2M+34.4%	$32.6M-21.7%	$30.4M-30.2%	$34.1M-16.5%	$41.1M-7.3%	$41.6M+47.8%
Income Tax	$14.0M+326.5%	$347K-99.5%	-$4.1M+85.7%	-$39.0M-549.8%	-$6.2M-146.1%	$63.3M+819.6%	-$28.8M-2188.6%	$8.7M+125.8%
Net Income	$83.5M+228.8%	-$2.8M-100.3%	-$134.6M-104.3%	$15.9M+114.9%	-$64.8M+34.6%	$866.6M+1046.3%	-$65.9M+57.7%	-$106.7M+19.8%
EPS (Basic)	$1.01+221.7%	-$0.03-100.3%	-$1.82-114.1%	$0.20+114.4%	-$0.83+35.7%	$11.09+1024.2%	-$0.85+58.7%	-$1.39+21.0%
EPS (Diluted)	$0.92+210.8%	-$0.03-100.3%	-$1.67-96.5%	$0.20+114.4%	-$0.83+35.7%	$10.04+936.7%	-$0.85+58.7%	-$1.39+21.0%
Diluted Shares (Avg)	92M+17.7%	83M-4.5%	N/A	87M+13.2%	78M+1.9%	86M+12.9%	N/A	77M+2.1%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

PTCT Balance Sheet

PTCT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$2.9B+70.0%	$1.7B-10.1%	$1.9B+11.1%	$1.7B-12.0%	$1.9B-12.2%	$2.2B+36.0%	$1.6B+45.1%	$1.1B+185.8%	$391.7M+45.4%	$269.3M-26.3%	$365.3M+9.6%	$333.2M+119.4%	$151.9M+1062.0%	$13.1M	N/A
Current Assets	$2.3B+66.5%	$1.4B+12.1%	$1.2B+75.6%	$693.8M-27.3%	$954.4M-22.5%	$1.2B+58.1%	$779.3M+142.9%	$320.9M+28.8%	$249.1M-4.7%	$261.3M-26.6%	$355.9M+10.0%	$323.6M+123.1%	$145.0M+3055.9%	$4.6M	N/A
Cash & Equivalents	$984.6M+26.3%	$779.7M+31.3%	$594.0M+112.3%	$279.8M+47.5%	$189.7M-9.1%	$208.8M-27.5%	$288.0M+69.9%	$169.5M+51.6%	$111.8M+91.7%	$58.3M+0.5%	$58.0M+16.6%	$49.7M+222.7%	$15.4M+465.4%	$2.7M-90.4%	$28.4M
Short-Term Investments	$960.7M+166.9%	$360.0M+27.3%	$282.7M+116.0%	$130.9M-77.6%	$583.7M-34.8%	$894.8M+124.5%	$398.5M+586.1%	$58.1M-26.9%	$79.5M-54.2%	$173.3M-38.3%	$280.9M+5.8%	$265.5M+109.0%	$127.1M	$0	$0
Inventory	$79.6M+243.4%	$23.2M-24.1%	$30.6M+40.2%	$21.8M+37.5%	$15.9M-15.2%	$18.7M-3.0%	$19.3M+19.7%	$16.1M+49.9%	$10.8M	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$958K	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M	$0	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.1B+10.7%	$2.8B+3.3%	$2.7B+32.2%	$2.1B+6.0%	$1.9B+12.2%	$1.7B+67.7%	$1.0B+34.0%	$768.5M+226.7%	$235.2M+57.1%	$149.8M+7.5%	$139.3M+300.8%	$34.8M+126.2%	$15.4M-86.4%	$112.7M	N/A
Current Liabilities	$968.4M+66.7%	$581.0M-3.7%	$603.1M+48.5%	$406.2M-20.2%	$509.3M+83.7%	$277.3M+17.6%	$235.9M+41.4%	$166.8M+103.3%	$82.0M+65.3%	$49.6M+9.3%	$45.4M+39.8%	$32.5M+147.3%	$13.1M-53.4%	$28.2M	N/A
Non-Current Liabilities	$2.1B-3.9%	$2.2B+5.3%	$2.1B+28.2%	$1.6B+15.4%	$1.4B-1.5%	$1.4B+82.6%	$793.6M+31.9%	$601.7M+292.8%	$153.2M+53.0%	$100.1M+6.7%	$93.9M+4023.6%	$2.3M+2.2%	$2.2M-97.4%	$84.6M	N/A
Long-Term Debt	N/A	$285.4M+0.4%	$284.2M-50.3%	$571.7M+102.8%	$281.9M-8.8%	$309.1M+5.2%	$293.9M+107.9%	$141.3M-2.5%	$145.0M+47.6%	$98.2M+6.9%	$91.8M	N/A	N/A	$439K	N/A
Total Equity	-$205.3M+81.3%	-$1.1B-34.1%	-$818.6M-135.8%	-$347.1M-24236.7%	$1.4M-99.7%	$482.0M-18.9%	$594.3M+69.5%	$350.7M+124.2%	$156.4M+30.8%	$119.6M-47.1%	$226.0M-24.3%	$298.5M+118.6%	$136.5M+237.0%	-$99.6M+58.2%	-$238.6M
Retained Earnings	-$3.0B+18.7%	-$3.6B-11.1%	-$3.3B-23.6%	-$2.7B-26.6%	-$2.1B-28.8%	-$1.6B-36.8%	-$1.2B-26.8%	-$938.9M-15.3%	-$814.1M-10.7%	-$735.1M-24.0%	-$593.0M-40.3%	-$422.6M-28.5%	-$328.8M-18.6%	-$277.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$3.3B+23.4%	$2.9B+8.0%	$2.9B+70.0%	$2.6B+43.5%	$2.6B+37.5%	$2.7B+48.4%	$1.7B-10.1%	$1.8B+46.2%
Current Assets	$2.6B+15.2%	$2.3B-2.7%	$2.3B+66.5%	$2.0B+56.7%	$2.3B+67.4%	$2.3B+98.2%	$1.4B+12.1%	$1.3B+137.2%
Cash & Equivalents	$1.0B+3.2%	$834.0M-43.7%	$984.6M+26.3%	$672.6M+27.9%	$1.0B+55.4%	$1.5B+169.9%	$779.7M+31.3%	$526.0M+218.5%
Short-Term Investments	$1.2B+21.3%	$1.1B+93.5%	$960.7M+166.9%	$1.0B+108.3%	$971.8M+121.6%	$547.0M+62.6%	$360.0M+27.3%	$487.4M+275.9%
Inventory	$91.4M+168.2%	$75.6M+248.6%	$79.6M+243.4%	$52.7M+47.7%	$34.1M+7.0%	$21.7M-27.9%	$23.2M-24.1%	$35.7M-0.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%	$82.3M0.0%
Total Liabilities	$3.4B+20.2%	$3.0B+7.3%	$3.1B+10.7%	$2.8B-3.4%	$2.8B-1.9%	$2.8B+5.9%	$2.8B+3.3%	$2.9B+50.0%
Current Liabilities	$771.1M+22.8%	$923.6M+55.1%	$968.4M+66.7%	$866.2M+41.8%	$627.8M+3.0%	$595.4M+3.6%	$581.0M-3.7%	$610.7M+24.1%
Non-Current Liabilities	$2.6B+19.5%	$2.1B-5.3%	$2.1B-3.9%	$1.9B-15.4%	$2.2B-3.2%	$2.2B+6.5%	$2.2B+5.3%	$2.3B+58.9%
Long-Term Debt	$535.5M+87.2%	N/A	N/A	N/A	$286.0M+0.4%	$285.7M+0.4%	$285.4M+0.4%	$285.1M-50.3%
Total Equity	-$165.4M+19.9%	-$180.5M+2.9%	-$205.3M+81.3%	-$155.8M+85.2%	-$206.5M+78.9%	-$185.8M+79.2%	-$1.1B-34.1%	-$1.1B-57.2%
Retained Earnings	-$2.9B-1.3%	-$3.0B-6.7%	-$3.0B+18.7%	-$2.8B+21.0%	-$2.8B+18.1%	-$2.8B+17.6%	-$3.6B-11.1%	-$3.6B-14.5%

Not reported in any period shown, so not listed: Accounts Receivable.

PTCT Cash Flow Statement

PTCT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$30.5M	$711.2M+760.4%	-$107.7M+32.0%	-$158.4M+55.6%	-$356.7M-41.9%	-$251.3M-29.5%	-$194.1M-96.7%	-$98.6M-256.9%	-$27.6M-174.7%	-$10.1M+90.3%	-$103.6M+16.7%	-$124.3M-117.1%	-$57.3M-22.1%	-$46.9M+2.1%	-$47.9M-130.8%	-$20.8M
Depreciation & Amortization	N/A	$38.8M-48.7%	$75.7M-68.0%	$236.6M+83.6%	$128.8M+100.9%	$64.1M+47.5%	$43.5M+35.1%	$32.2M+23.4%	$26.1M+47.5%	$17.7M+437.4%	$3.3M+14.4%	$2.9M+28.7%	$2.2M-6.7%	$2.4M-11.4%	$2.7M-5.8%	$2.9M
Stock-Based Compensation	N/A	$74.5M-0.1%	$74.6M-26.6%	$101.6M-7.9%	$110.3M+6.6%	$103.5M+47.2%	$70.3M+66.9%	$42.1M+26.7%	$33.3M+8.8%	$30.6M-12.7%	$35.0M+3.0%	$34.0M+76.0%	$19.3M+129.1%	$8.4M+268.2%	$2.3M-18.7%	$2.8M
Capital Expenditures	$9.3M	$8.9M+36.3%	$6.5M-77.1%	$28.4M-11.2%	$32.0M+13.5%	$28.2M+58.1%	$17.8M+29.7%	$13.8M+93.8%	$7.1M+128.9%	$3.1M+74.6%	$1.8M-34.7%	$2.7M-41.7%	$4.7M+451.3%	$846K+347.6%	$189K+14.5%	$165K
Free Cash Flow	-$39.8M	$702.3M+715.1%	-$114.2M+38.9%	-$186.9M+51.9%	-$388.7M-39.0%	-$279.5M-31.9%	-$211.9M-88.5%	-$112.4M-223.6%	-$34.7M-163.9%	-$13.2M+87.5%	-$105.3M+17.1%	-$127.1M-105.1%	-$61.9M-29.7%	-$47.8M+0.7%	-$48.1M-129.9%	-$20.9M
Investing Cash Flow	-$471.9M	-$862.0M-2051.0%	$44.2M+125.0%	-$176.7M-160.9%	$290.2M+32.4%	$219.2M+139.0%	-$561.5M-45.0%	-$387.2M-808.7%	-$42.6M-424.9%	$13.1M-87.4%	$104.5M+602.0%	-$20.8M+85.7%	-$145.2M	N/A	N/A	N/A
Financing Cash Flow	$536.0M	$331.1M+29.4%	$255.9M-60.4%	$646.4M+284.9%	$168.0M+704.5%	$20.9M-96.9%	$668.7M+9.1%	$613.2M+366.1%	$131.6M+197.6%	$44.2M+4468.0%	$968K-99.4%	$154.1M-35.0%	$237.1M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$129.1M+321.3%	-$59.0M-106.8%	-$34.3M-14.2%	-$66.3M+13.9%	-$58.3M+18.4%	$870.1M+1129.6%	-$30.0M+70.1%	-$77.0M-430.3%
Depreciation & Amortization	$15.9M+109.3%	$15.4M+113.4%	$12.9M+90.7%	$11.1M+71.3%	$7.6M+8.1%	$7.2M-87.0%	$6.8M-91.6%	$6.5M-89.5%
Stock-Based Compensation	$23.3M+25.6%	$23.4M+29.7%	N/A	$19.4M-1.7%	$18.5M-3.6%	$18.1M-1.7%	N/A	$19.8M-26.7%
Capital Expenditures	$2.2M+75.8%	$1.2M-30.6%	$2.4M-37.0%	$3.5M+573.4%	$1.2M-83.1%	$1.7M-82.0%	$3.8M-32.3%	$522K-91.8%
Free Cash Flow	$126.9M+313.0%	-$60.2M-106.9%	-$36.6M-8.5%	-$69.8M+9.9%	-$59.6M+24.4%	$868.4M+1319.5%	-$33.8M+68.1%	-$77.5M-271.3%
Investing Cash Flow	-$122.6M+71.0%	-$93.7M+49.2%	$34.0M-87.3%	-$289.6M-578.7%	-$422.0M-540.2%	-$184.4M-60.4%	$267.7M+383.5%	-$42.7M-44.2%
Financing Cash Flow	$211.9M+5249.1%	$6.4M-32.0%	$302.5M+1042.8%	$15.2M+186.3%	$4.0M-98.4%	$9.4M+1642.6%	$26.5M-95.7%	-$17.6M-624.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PTCT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PTCT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	96.0%+0.8pp	95.2%-2.4pp	97.7%-2.3pp	100.0%0.0pp	100.0%	N/A	N/A	N/A	N/A
Operating Margin	50.1%+87.6pp	-37.5%+9.4pp	-46.9%+17.2pp	-64.0%+5.5pp	-69.5%	-113.4%	-78.6%-34.9pp	-43.7%-10.6pp	-33.1%	-159.7%	-454.6%	-393.8%	-130.8%	-79.0%-108.0pp	29.0%
Net Margin	39.5%+84.5pp	-45.0%+21.8pp	-66.8%+13.2pp	-80.0%+17.3pp	-97.3%	-115.1%	-82.0%-33.6pp	-48.4%-7.7pp	-40.6%	-171.8%	-463.6%	-371.4%	-148.7%	-77.3%-106.6pp	29.3%
Return on Equity	N/A	N/A	N/A	N/A	-36432.5%-36341.6pp	-90.9%-48.6pp	-42.3%-5.8pp	-36.5%+14.0pp	-50.5%+68.3pp	-118.8%-43.4pp	-75.4%-44.0pp	-31.4%+6.4pp	-37.8%	N/A	N/A
Return on Assets	23.6%+44.9pp	-21.3%+11.7pp	-33.1%-0.3pp	-32.8%-5.7pp	-27.0%-7.2pp	-19.8%-4.3pp	-15.5%-4.1pp	-11.4%+8.7pp	-20.2%+32.6pp	-52.8%-6.1pp	-46.7%-18.5pp	-28.1%+5.8pp	-34.0%+166.7pp	-200.7%	N/A
Current Ratio	2.350.0x	2.35+0.3x	2.02+0.3x	1.71-0.2x	1.87-2.6x	4.44+1.1x	3.30+1.4x	1.92-1.1x	3.04-2.2x	5.27-2.6x	7.84-2.1x	9.96-1.1x	11.04+10.9x	0.16	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	196.03+195.4x	0.64+0.1x	0.49+0.1x	0.40-0.5x	0.93+0.1x	0.82+0.4x	0.41+0.3x	0.120.0x	0.11	N/A	N/A
Asset Turnover	0.60+0.1x	0.470.0x	0.49+0.1x	0.41+0.1x	0.28+0.1x	0.170.0x	0.190.0x	0.24-0.3x	0.50+0.2x	0.31+0.2x	0.100.0x	0.08-0.2x	0.23-2.4x	2.60	N/A
FCF Margin	40.6%+54.7pp	-14.1%+5.8pp	-19.9%+35.7pp	-55.6%-3.7pp	-51.9%+3.7pp	-55.6%-19.0pp	-36.6%-23.5pp	-13.1%-6.4pp	-6.8%	-127.4%	-345.6%	-245.3%	-137.7%	-141.8%	-19.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	41.3%+60.9pp	16.5%-66.0pp	-43.3%+32.9pp	1.4%+29.1pp	-19.5%+2.0pp	82.5%+104.1pp	-76.2%-78.1pp	-27.7%+32.4pp
Net Margin	23.2%+59.4pp	-1.0%-74.7pp	-81.7%-50.8pp	7.5%+61.7pp	-36.3%+16.9pp	73.7%+117.3pp	-30.9%+19.8pp	-54.2%+13.4pp
Return on Assets	2.6%+5.0pp	-0.1%-32.7pp	-4.6%-0.8pp	0.6%+6.4pp	-2.5%+2.7pp	32.6%+37.8pp	-3.9%+4.4pp	-5.8%+4.8pp
Current Ratio	3.39-0.2x	2.44-1.5x	2.350.0x	2.32+0.2x	3.62+1.4x	3.89+1.9x	2.35+0.3x	2.10+1.0x
Asset Turnover	0.110.0x	0.10-0.3x	0.06-0.1x	0.080.0x	0.070.0x	0.44+0.3x	0.130.0x	0.110.0x
FCF Margin	35.2%+68.5pp	-22.1%-95.9pp	-22.3%-6.4pp	-33.1%+6.3pp	-33.3%+8.9pp	73.8%+44.7pp	-15.8%+18.6pp	-39.4%-28.8pp

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$205.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
PTC Therapeutics, Inc. PTCT	FY2025	$1.7B	$683.0M	39.5%	$5.4B	53/100
Merus N.V. MRUS	FY2024	$36.1M	-$215.3M	N/A	$6.8B	59/100
TG Therapeutics, Inc. TGTX	FY2025	$616.3M	$447.2M	72.6%	$8.5B	60/100
CRISPR Therapeutics AG CRSP	FY2025	$3.5M	-$581.6M	N/A	$5.2B	53/100
Krystal Biotech, Inc. KRYS	FY2025	$389.1M	$204.8M	52.6%	$9.8B	59/100

Where PTC Therapeutics, Inc. Ranks

Frequently Asked Questions

What is PTC Therapeutics, Inc.'s annual revenue?

PTC Therapeutics, Inc. (PTCT) reported $1.7B in total revenue for fiscal year 2025. This represents a 114.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is PTC Therapeutics, Inc.'s revenue growing?

PTC Therapeutics, Inc. (PTCT) revenue grew by 114.5% year-over-year, from $806.8M to $1.7B in fiscal year 2025.

Is PTC Therapeutics, Inc. profitable?

Yes, PTC Therapeutics, Inc. (PTCT) reported a net income of $683.0M in fiscal year 2025, with a net profit margin of 39.5%.

What is PTC Therapeutics, Inc.'s EBITDA?

PTC Therapeutics, Inc. (PTCT) had EBITDA of $905.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is PTC Therapeutics, Inc.'s operating margin?

PTC Therapeutics, Inc. (PTCT) had an operating margin of 50.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is PTC Therapeutics, Inc.'s net profit margin?

PTC Therapeutics, Inc. (PTCT) had a net profit margin of 39.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is PTC Therapeutics, Inc.'s free cash flow?

PTC Therapeutics, Inc. (PTCT) generated $702.3M in free cash flow during fiscal year 2025. This represents a 715.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is PTC Therapeutics, Inc.'s operating cash flow?

PTC Therapeutics, Inc. (PTCT) generated $711.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are PTC Therapeutics, Inc.'s total assets?

PTC Therapeutics, Inc. (PTCT) had $2.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are PTC Therapeutics, Inc.'s capital expenditures?

PTC Therapeutics, Inc. (PTCT) invested $8.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does PTC Therapeutics, Inc. spend on research and development?

PTC Therapeutics, Inc. (PTCT) invested $455.2M in research and development during fiscal year 2025.

How many shares does PTC Therapeutics, Inc. have outstanding?

PTC Therapeutics, Inc. (PTCT) had 83M shares outstanding as of fiscal year 2025.

What is PTC Therapeutics, Inc.'s current ratio?

PTC Therapeutics, Inc. (PTCT) had a current ratio of 2.35 as of fiscal year 2025, which is generally considered healthy.

What is PTC Therapeutics, Inc.'s return on assets (ROA)?

PTC Therapeutics, Inc. (PTCT) had a return on assets of 23.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is PTC Therapeutics, Inc.'s P/E ratio?

PTC Therapeutics, Inc. (PTCT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $5.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is PTC Therapeutics, Inc.'s price-to-sales ratio?

PTC Therapeutics, Inc. (PTCT) trades at 5.4x sales, its market capitalization divided by revenue of $1.0B revenue, trailing 12 months to June 30, 2026. The market capitalization is $5.4B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is PTC Therapeutics, Inc.'s debt-to-equity ratio negative or not reported?

PTC Therapeutics, Inc. (PTCT) has negative shareholder equity of -$205.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is PTC Therapeutics, Inc.'s Altman Z-Score?

PTC Therapeutics, Inc. (PTCT) has an Altman Z-Score of 1.74, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is PTC Therapeutics, Inc.'s Piotroski F-Score?

PTC Therapeutics, Inc. (PTCT) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PTC Therapeutics, Inc.'s earnings high quality?

PTC Therapeutics, Inc. (PTCT) has an earnings quality ratio of 1.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can PTC Therapeutics, Inc. cover its interest payments?

PTC Therapeutics, Inc. (PTCT) has an interest coverage ratio of 5.69x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is PTC Therapeutics, Inc.?

PTC Therapeutics, Inc. (PTCT) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.